HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure
- 15 May 2014
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 28 (8) , 1125-1134
Abstract
Background: The clinical implications of emergent HIV drug resistance on samples with low-level viraemia (LLV P < 0.001). Numerous sensitivity analyses confirmed these findings. Conclusion: Our results demonstrate that emergent HIV drug resistance at LLV is strongly associated with subsequent virologic failure. Furthermore, we uncovered a ‘dose-dependent’ increase in the hazard ratio for virologic failure with decreasing GSS estimated at the time of LLV. On the basis of these findings, we propose that resistance genotyping be encouraged for HIV-infected individuals on antiretroviral therapy experiencing low-level viraemia.Keywords
This publication has 39 references indexed in Scilit:
- Prevalence and Significance of HIV-1 Drug Resistance Mutations among Patients on Antiretroviral Therapy with Detectable Low-Level ViremiaAntimicrobial Agents and Chemotherapy, 2012
- British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012HIV Medicine, 2012
- Automating HIV Drug Resistance Genotyping with RECall, a Freely Accessible Sequence Analysis ToolJournal of Clinical Microbiology, 2012
- Short-Term Clinical Outcomes Among Treatment-Experienced HIV-Positive Patients with Early Low Level ViremiaAIDS Patient Care and STDs, 2012
- Magnitude of Virologic Blips Is Associated With a Higher Risk for Virologic Rebound in HIV-Infected Individuals: A Recurrent Events AnalysisThe Journal of Infectious Diseases, 2012
- Plasma HIV-1 RNA Levels During Antiretroviral Therapy: How Low Is Low Enough?Clinical Infectious Diseases, 2012
- Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremiaAIDS, 2011
- Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance DetectionClinical Infectious Diseases, 2010
- Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapyProceedings of the National Academy of Sciences, 2008
- Web Resources for HIV Type 1 Genotypic-Resistance Test InterpretationClinical Infectious Diseases, 2006